The research of my group is centred on the immunology of skin cancers (melanoma, cutaneous lymphomas, epithelial cancers) and aims at understanding the antigenicity of tumour cells and regulation including the reasons for failure of tumour-specific immune responses. It is patient-based and translational. We employ all available technologies for antigen discovery such as proteome serology and seroscreening of expression libraries for antigens recognised by antibodies, and peptidomics involving extraction, isolation by HPLC and sequencing by mass spectrometry of peptides bound by major histocompatibility (MHC) molecules (HLA) plus sequence screens and bioinformatics to define T cell epitopes. Together with epitope design by molecular library and bioinformatics approaches this is used to develop T cell-directed vaccines. We use multiparameter flow cytometry with up to 14 colours, real-time PCR and toponomics (multiepitope immunohistochemistry with 200 and more specificities) to unravel the immune-regulatory processes in cancer. From these works we can expect information on molecular-pathological processes in cancer as sensed by the immune system, and leads for new strategies and targets for immunotherapy some of which have already been tested in clinical trials.